CO-BONA
18.3.2024 09:06:33 CET | Business Wire | Press release
Today, Bona® announced that four of its products are now certified by the U.S. Environmental Protection Agency (EPA) Safer Choice program and have earned the Safer Choice label. The new certification applies to the Bona Pet System™ including Bona Pet System™ Hard-Surface Floor Deep Cleaner and Bona Pet System™ Wood Floor Deep Cleaner as well as Bona’s OxyPower floor cleaners -- Bona OxyPower Hard-Surface Floor Deep Cleaner and Bona OxyPower Wood Floor Deep Cleaner. Safer Choice is a voluntary EPA program that certifies cleaning and other products made with ingredients that are safer for people, pets, and the planet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318768884/en/
Bona Pet System™ and Bona OxyPower Products Receive Environmental Protection Agency Safer Choice Certification (Graphic: Business Wire)
“As we continue our journey to innovate cleaning solutions that bring out the beauty in floors, our primary focus is to leverage the latest technologies and research when it comes to ingredients,” said Marie Shore, Director Product Management EMEA & APAC, Bona.“Recognition like this one from the EPA Safer Choice program is a key milestone in validating our work for a more sustainable future.”
The Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. Every ingredient in products that carry the Safer Choice label is reviewed by EPA scientists to make sure certified products only contain the safest possible ingredients for people and the planet. Safer Choice-certified products are made with ingredients that won't cause serious health problems, like cancer, and aren't harmful to fish or waterways. Safer Choice also restricts volatile organic compounds to minimize indoor air pollution and associated respiratory concerns. Products with the label also use more sustainable packaging that doesn't contain toxic chemicals, like heavy metals.
Powered by hydrogen peroxide, Bona OxyPower Wood Floor Deep Cleaner and Bona OxyPower Hard-Surface Floor Deep Cleaner are specifically designed to remove heavy dirt build-up, providing a deep clean for wood or hard-surface floors. The ready-to-use, oxygenated, waterbased formula releases thousands of micro-bubbles that loosen heavy dirt build-up, removes stuck-on messes, and lifts away stains via a bubbling action to provide a deep clean for floors.
Formulated specifically for cleaning pet messes, The Bona Pet System Hard Surface Floor Deep Cleaner and Bona Pet System Wood Floor Deep Cleaner offer a deep clean by penetrating through tough stuck-on stains, tracked in dirt, and accident messes with the cleaning power of Hydrogen Peroxide. The Odour Guard Technology™ eliminates and neutralizes urine and other organic odours upon contact.
For more information about Bona Pet System and OxyPower cleaners are visit www.bona.com. These GREENGUARD certified products are available in EMEA and APAC regions.
“These four cleaning products were developed to meet the high standards of consumers as well as certifying organizations like the EPA Safer Choice program,” continued Shore. “With 11 Safer Choice certified products in North America it made sense to seek this certification for our products in Europe. It all aligns to our long-standing mission to minimize our environmental impact by innovating safer systems and products to the highest sustainability standards.”
About the EPA Safer Choice Program
Safer Choice incentivizes safer, greener chemistry by allowing companies to differentiate their products in the marketplace with the Safer Choice label. With thousands of certified products, the Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. For more information about the Safer Choice program, visit: www.epa.gov/saferchoice.
About Bona®
Bona® is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 4.1bn SEK (EUR 366million) 2023. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318768884/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
